Abstract
The aim of this study was to determine the antitumor activity of 13-cis-retinoic acid as a single agent in patients with advanced renal cell carcinoma. Eligible patients had advanced renal cell carcinoma with bi-dimensionally measurable disease, a Karnofsky performance status of at least 70, life expectancy of greater than three months, no evidence of brain metastases, and treatment with no more than one chemotherapy regimen. Patients were treated with one mg/kg/day of 13-cis-retinoic acid orally. Twenty-six patients were enrolled in this study and 25 were evaluable for response and toxicity. Of the twenty-five evaluable patients, no major responses were achieved. Toxicity was mild, with no patient requiring a dose reduction. At the dose administered in this trial, 13-cis-retinoic acid is inactive as a single agent in renal cell carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Motzer RJ, Bander NH, Nanus DM: Medical progress: Renalcell carcinoma. New Engl J Med 335:865–875, 1996
Motzer RJ, Vogelzang NJ: Chemotherapy for renal cell carcinoma. In: Raghaven D, Scher HI, Leibel SA, Lange P (eds) Principles and Practice of Genitourinary Oncology. Lippincott-Raven, Philadelphia, 1997, pp 885–896
Motzer RJ, Schwartz L, Murray Law T, Murphy BA, Hoffman AD, Albino AP, Vlamis V, Nanus DM: Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: Antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 13:1950–1957, 1995
Murray Law T, Motzer RJ, Minasian LM, Mazumdar M, Lyn P, Kampel L: Risk stratification in advanced renal cell carcinoma: A single institution study of 237 patients (Abstract). Proc Amer Soc Clin Oncol 13:243, 1994
Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE: Interferon alfa-2a in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11:1368–1375, 1993
Ilson DH, Motzer RJ, Kradin RL, Vogelzang NJ, Bajorin DF, Scher HI, Nanus D, O'Moore P, Marathias K, Bosl GJ: A phase II trial of interleukin-2 and interferon alfa 2a in patients wit advanced renal cell carcinoma. J Clin Oncol 10:1124–1130, 1992
Murray Law T, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O'Connell M, Khan A, Vlamis V, Vogelzang N, Bajorin DF: Phase III randomized trial of interleukin-2 with or without lymphine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76:824–832, 1995
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981
Hoffman AD, Engelstein D, Bogenrieder T, Papandreou CN, Steckelman E, Dave A, Motzer RJ, Dmitrovsky E, Albino A, Nanus DM: Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid. Clin Cancer Res 2:1077–1082, 1996
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Berg, W.J., Schwartz, L.H., Amsterdam, A. et al. A Phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Invest New Drugs 15, 353–355 (1997). https://doi.org/10.1023/A:1005902022076
Issue Date:
DOI: https://doi.org/10.1023/A:1005902022076